GHK-Cu
Evidence: C/DRepair / Tissue Healing
Evidence Snapshot
What this grade covers
C for topical/cosmetic and preclinical extracellular-matrix, fibroblast, collagen, wound, redox, and signaling-biology evidence supporting mechanistic investigation, and for an older, manufacturer-funded, multicenter randomized placebo-controlled diabetic-neuropathic-ulcer trial that reported significantly faster and more complete topical wound closure than vehicle but has not been independently, non-industry-replicated in the decades since; D for a small topical post-laser human study showing no significant objective advantage for erythema, wrinkles, or overall skin quality, and for secondary review-level anti-aging discussion; E for systemic/injectable efficacy, safety, and dosing, and for any broad anti-aging, hair-growth, or wound-treatment outcome beyond what these topical studies support, since topical/cosmetic and finished-product studies do not establish injectable efficacy or safety and no FDA-approved injectable GHK-Cu product or dosing regimen was identified. FDA's separate compounding-safety concerns for injectable GHK-Cu (aggregation, impurity, and immunogenicity risk) are a route-specific regulatory finding, distinct from the topical efficacy evidence described above.
Regulatory Context
No FDA-approved injectable GHK-Cu drug product was identified. FDA states that compounded injectable GHK-Cu may pose immunogenicity risks because of aggregation and peptide-related impurities and that human data are limited. As of May 14, 2026, GHK-Cu excluding injectable routes was listed in 503A Category 1 under evaluation; Category 1 status is not approval, authorization, or a finding of safety or effectiveness.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine (GHK) bound to a copper(II) ion, forming a distinct copper-peptide complex. It is chemically different from copper-free GHK, which MitoCore covers as its own separate page — evidence for one should not be assumed to apply to the other. GHK-Cu has been studied in two very different contexts — topical/cosmetic skin application and separately, compounded injectable use — and evidence from one route does not establish the other.
Why are researchers interested in it?
Researchers have studied topical GHK-Cu in skin-remodeling, wound-healing, and cosmetic contexts, including small human trials of creams or serums, alongside cell and tissue work on collagen-related gene expression, fibroblast behavior, and antioxidant/signaling effects. Injectable/compounded GHK-Cu has instead drawn regulatory attention through FDA's bulk-drug-substance compounding review process — a regulatory evaluation, not a clinical efficacy study.
What is it being studied for?
- Topical skin appearance, remodeling & wound healingHuman Studies & Clinical Data
- Collagen / extracellular-matrix cell biologyAnimal / Cell / Preclinical Data
- Injectable / systemic useAnimal / Cell / Preclinical Data
- FDA compounding-substance review (503A category status)Regulatory Documents & Official Trial Registries
What does the evidence look like?
Topical GHK-Cu has two notable human studies with different results. An older multicenter, randomized, placebo-controlled trial in patients with diabetic foot ulcers reported significantly faster and more complete healing with a topical GHK-Cu gel than placebo — but it was funded by the product's manufacturer, is several decades old, and no independent, non-industry-funded replication was identified. A separate, small post-laser human study found no significant objective advantage for erythema, wrinkles, or overall skin quality versus comparison treatment. Beyond these two studies, the remaining supporting science is preclinical/cell-based (extracellular-matrix, fibroblast, collagen, redox, and signaling biology). No human clinical-trial evidence for injectable or systemic GHK-Cu was identified; injectable use is supported only by preclinical/mechanistic reasoning, not by topical-route findings, which do not transfer to systemic administration regardless of the topical result. FDA has stated compounded injectable GHK-Cu may pose immunogenicity risks from aggregation and impurities, and that human data are limited.
Biggest things to know
GHK-Cu is not the same subject as copper-free GHK — this page covers only the copper complex. No FDA-approved injectable GHK-Cu drug product exists, and FDA has said compounded injectable GHK-Cu may pose immunogenicity risks from aggregation and peptide-related impurities. As of FDA's most recent published update (May 14, 2026), non-injectable GHK-Cu sits in 503A Category 1 — nominated and under evaluation, which is not approval, authorization, or a safety/effectiveness finding. FDA has scheduled a Pharmacy Compounding Advisory Committee review of GHK-Cu for before the end of February 2027. Topical human evidence is mixed: an older, manufacturer-funded trial reported significantly better diabetic-ulcer healing with GHK-Cu gel than placebo, but it has not been independently replicated, while a separate, small post-laser cosmetic study found no significant skin-appearance benefit. Neither result extends to injectable or systemic use, and broad 'anti-aging' framing goes beyond what the actual measured outcomes show.
What don't we know yet?
Whether injectable/systemic GHK-Cu is safe or effective in humans, at any dose, is unknown — no human clinical-trial evidence was identified for that route. How compounded injectable GHK-Cu's purity, aggregation, and impurity profile affects real-world immunogenicity risk in humans is also unknown. Whether the positive diabetic-ulcer healing result would replicate in an independent, non-industry-funded trial is unknown — no such replication was identified. Long-term outcomes and optimal dosing for topical use are not fully defined, and what FDA's upcoming Pharmacy Compounding Advisory Committee review (scheduled before February 2027) will conclude is not yet known.
Research status
Reviewed August 25, 2026
Research Takeaway
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine.
See all 10 evidence claims →Quick Summary
GHK-Cu is the copper(II) complex of the tripeptide GHK. Research includes cell, animal, formulation, biomaterial, and limited topical human studies. The available topical human evidence does not establish broad anti-aging, hair-growth, or wound-treatment efficacy, and it cannot support systemic injectable claims. FDA separately identifies aggregation, peptide-impurity, immunogenicity, and limited-human-data concerns for compounded injectable GHK-Cu.
Mechanism & Research Overview
GHK-Cu binds copper and has been studied in extracellular-matrix, fibroblast, collagen, wound, redox, and signaling biology. Copper coordination, oxidation state, pH, concentration, excipients, delivery system, and route can materially affect identity and behavior. Findings for copper-free GHK, AHK-Cu, cosmetic blends, topical products, microneedle systems, injectable biomaterials, or compounded injections cannot be transferred automatically to GHK-Cu in another formulation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine.
Supported
GHK-Cu is distinct from copper-free GHK, AHK-Cu, unspecified copper peptides, and multi-peptide blends.
Supported
Cell and preclinical studies support investigation of extracellular-matrix, fibroblast, collagen, wound, redox, and signaling biology.
Sources: Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+; GHK-Cu and Extracellular Matrix in Wounds; GHK-Cu MMP/TIMP Modulation in Fibroblasts
Supported
A small topical post-laser human study did not show significant objective advantage for erythema, wrinkles, or overall skin quality.
Sources: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
Supported
Topical, microneedle, biomaterial, and finished-product studies cannot establish systemic injectable efficacy or safety.
Sources: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin; Topical GHK-Cu Gel for Acute Skin Wound Healing
Supported
Copper coordination, pH, concentration, excipients, container conditions, and delivery system can affect formulation behavior.
Supported
FDA identifies potential aggregation, peptide-impurity, immunogenicity, and limited-human-data concerns for compounded injectable GHK-Cu.
Sources: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Supported
GHK-Cu excluding injectable routes was in 503A Category 1 under evaluation as of May 14, 2026; this is not approval.
Supported
No FDA-approved injectable GHK-Cu drug product or established injectable dosing regimen was identified.
Sources: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Supported
Registered or ongoing topical studies do not constitute completed efficacy evidence.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Systemic injectable efficacy and safety are not established by topical or cosmetic studies.Higher-Priority Safety Consideration
FDA has identified injectable aggregation, peptide-impurity, and immunogenicity concerns.Higher-Priority Safety Consideration
Unverified products may have incorrect copper content, identity, purity, sterility, or formulation.Safety Consideration
Copper coordination, pH, concentration, excipients, and container conditions can affect chemical identity and formulation behavior.Safety Consideration
Small topical studies do not establish broad anti-aging, hair-growth, or wound-treatment outcomes.
Research Areas Being Studied
Research areas discussed on this page reflect the Repair / Tissue Healing category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006): Topical copper-tripeptide regimen compared with control skin care.
- Topical GHK-Cu in Diabetic Neuropathic Ulcers ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin | 2006 | Thirteen patients after CO2 laser skin resurfacing | Topical copper-tripeptide regimen compared with control skin care. | Small study; subjective satisfaction differed while objective outcomes did not. | |
| Topical GHK-Cu in Diabetic Neuropathic Ulcers | A multicenter, randomized, evaluator-blinded, vehicle-controlled study of a topical glycyl-L-histidyl-L-lysine:copper complex gel alongside standardized wound care reported greater closure of diabetic neuropathic plantar ulcers and fewer infections than vehicle. The evidence is old, concerns a specific topical gel and standardized wound-care protocol, and does not establish injectable efficacy or generalized healing of tendons, ligaments, muscle, joints, nerves, or surgical wounds. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties | 2011 | Chemical structural and solution analysis | X-ray and spectroscopic characterization of Cu(II)-GHK. | Chemical characterization does not establish clinical use. | |
| Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ | 1988 | Cultured fibroblasts | In vitro collagen-synthesis experiment. | Cell-culture findings do not establish human efficacy or injectable safety. | |
| GHK-Cu and Extracellular Matrix in Wounds | Preclinical work on GHK-Cu and extracellular-matrix remodeling in wound biology. Mechanistic/preclinical only -- does not establish a human treatment effect. | ||||
| GHK-Cu MMP/TIMP Modulation in Fibroblasts | In vitro fibroblast work reporting GHK-Cu modulation of matrix metalloproteinases and their inhibitors (MMP/TIMP). Mechanistic/preclinical only -- does not establish a human treatment effect. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Category 1 Update | 2026 | FDA 503A bulk-substance categorization | Non-injectable GHK-Cu under evaluation; injectable route excluded from this Category 1 entry. | Do not present Category 1 status as FDA approval or endorsement. | |
| Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks | 2026 | FDA safety and compounding review | Current FDA statement specific to injectable GHK-Cu. | Route-specific regulatory safety context; not an efficacy finding. | |
| Topical GHK-Cu Gel for Acute Skin Wound Healing | A Phase 2 randomized, double-blind, vehicle-controlled split-wound study of topical GHK-Cu gel in healthy adults began in 2026 and was recruiting as of the research cutoff. No results were posted. Trial registration is not evidence of safety or effectiveness. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The potential of GHK as an anti-aging peptide | 2022 | Review | Skin/wound/aging biology — Summarizes skin remodeling, wound healing, antioxidant, and anti-inflammatory effects. | Secondary source; useful for context but not a substitute for primary study review. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Topical, cosmetic, formulation, biomaterial, preclinical, and injectable evidence for GHK-Cu are not interchangeable. This page does not establish an approved systemic treatment, injectable benefit, cosmetic guarantee, or dosing regimen.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-26.
Follow research updates for GHK-Cu
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.